tbuckley/cabot-search huggingface dataset:
AB1350 THE KINETICS OF HUMORAL AND CELLULAR RESPONSES AFTER THE BOOSTER DOSE OF COVID-19 VACCINE IN INFLAMMATORY ARTHRITIS PATIENTS
Authors: J. Wroński, B. Jaszczyk, L. Roszkowski, A. Felis-Giemza, K. Bonek, A. Kornatka, M. Plebanczyk, T. Burakowski, B. Lisowska, B. Kwiatkowska, W. Maśliński, M. Wisłowska, M. Massalska, E. Kuca-Warnawin, M. Ciechomska
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Impaired immunogenicity of COVID-19 vaccinations in inflammatory arthritis (IA) patients results in diminished immunity. However, optimal booster vaccination regimens are still unknown, due to unstudied kinetics of the immune response after booster vaccinations. <h3>Objectives</h3> This study aimed to assess the kinetics of humoral and cellular responses in IA patients after the COVID-19 booster. <h3>Methods</h3> In 29 IA patients and 16 healthy controls (HC) humoral responses (level of IgG antibodies) and cellular responses (IFN-γ production) were assessed before (T0), after 4 weeks (T1), and after more than 6 months (T2) from the booster vaccination with BNT162b2. <h3>Results</h3> IA patients, but not HC, showed lower anti-S-IgG concentration and IGRA fold change at T2 compared to T1 (p=0.026 and p=0.031). Furthermore, in IA patients the level of cellular response at T2 returned to the pre-booster level (T0). All immunomodulatory drugs, except IL-6 and IL-17 inhibitors for the humoral and IL-17 inhibitors for the cellular response, impaired the immunogenicity of the booster dose at T2. However, none of the immunomodulatory drugs affected the kinetics of both humoral and cellular responses (measured as the difference between response rates at T1 and T2). <h3>Conclusion</h3> Our study showed impaired kinetics of both humoral and cellular responses after the booster dose of the COVID-19 vaccine in IA patients, which, in the case of cellular response, did not allow the vaccination effect to be maintained for more than 6 months. Repetitive vaccination with subsequent booster doses seems to be necessary for IA patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1270 ANALYSIS OF PREVALENCE AND RELATED RISK FACTORS OF HYPERURICEMIA IN BOZDUN AKSU PREFECTURE OF XINJIANG
Authors: Y. Zhong, L. Wu
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Objectives</h3> To investigate the prevalence of Hyperuricemia (HUA) in Bozidun Kirghiz Township, Aksu region, Xinjiang, and to explore the risk factors for the occurrence of HUA in the local area. <h3>Methods</h3> A cross-sectional survey study was conducted by randomly selecting 9 villages in Bozidun Kirgiz Township by the whole-group sampling method and using a questionnaire distributed to households. The questionnaire included: general information, history of previous diseases, personal history, and all subjects were measured for he-ight, weight, blood pressure, abdominal circumference, etc. The diagnostic of HUA: serum uric acid (SUA) &gt;420μmol/L in men or &gt;360μmol/L in women. <h3>Results</h3> ①A total of 2138 subjects were surveyed, among which 68 patients with HUA, the prevalence of HUA in Bozidun Kirghiz Township, Aksu regionrate general population was 3.2% (68/2138); the prevalence rate of men was 4.6%, with 45 patients; and the prevalence rate of women was 2.0%, with 23 patients. The peak age of male and female patients was 51~60 years old. ②The prevalence of HUA was lower in those who consumed dairy products, nuts and eggs, and lower in those who consumed more. Different intake of cereals, meat, vegetables and fruits had no effect on the prevalence of HUA.③In terms of different life behaviors, the prevalence of HUA in men who had been smoking was higher than those who had never smoked (57.78%, 28.89%, 13.33%, P=0.017). In the relationship between drinking and HUA, the prevalence rates of male always drinking, ever drinking and never drinking were 80.00%, 11.11% and 3.89%, respectively, showing significant differences(P=0.038);④Multi-factor logistic regression analysis showed that BMI, age, TG, Cr and WBC were risk factors for the occurrence of HUA. <h3>Conclusion</h3> The prevalence of HUA in Bozidun Kirgiz township in Aksu prefecture of Xinjiang is lower than that in other areas with continental climate. High body mass index, old age, high triglyceride, increased creatinine and increased white blood cell count are the risk factors for the development of HUA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1150 ORDER OF APPEARANCE OF PSORIASIS AND ARTHRITIS SYMPTOMS IN PSORIATIC ARTHRITIS: COMPARATIVE STUDY OF A RETROSPECTIVE COHORT
Authors: P. Moya Alvarado, H. S. Park, A. Laiz, A. Lopez-Ferrer, C. Marco Pascual, A. García-Alija, A. Casals Urquiza, C. Pitarch Grau, C. Diaz-Torne, B. Magallares, I. Castellví, S. Ros, S. P. Fernandez-Sanchez, H. Codes, L. Sainz Comas, A. M. Millán Arciniegas, J. L. Tandaipan, L. Puig, H. Corominas
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Little is known about the chronologic order of appearance of psoriasis (Pso) and psoriatic arthritis (PsA) symptoms and its effect on disease evolution. Most information is based on population-based registries or big data that may lack precision. <h3>Objectives</h3> To evaluate duration and chronologic order of appearance cutaneous and articular manifestations of PsA from 1<sup>st</sup> symptoms till diagnosis. To compare differences between patients with symptoms and diagnosis of Pso before PsA with those that manifest Pso after PsA. <h3>Methods</h3> A retrospective cohort study was conducted. Eligible patients were 219 patients that met ASAS criteria visited the SpA clinic between July – October 2022. Finally, 129 patients that met CASPAR criteria and Pso diagnosis were included. Other autoimmune rheumatic diseases were excluded. Data were collected previously reviewing patient records available from the electronic and paper database of the hospital. Additional information was retrieved by the shared medical history database of the Catalan Institute of Health which attends the 99.2% of the population. Missing data were collected prospectively by patient interview. ANOVA or Kruskall-Wallis test was carried out according to variable distribution. <h3>Results</h3> A total of 129 patients were included from which 98 had all time data related about disease appearance. There were 13.3% of missing data. The median disease evolution in years was 14 years with patients from 1 to 53 years of duration. The description and comparison of the clinical characteristics of each group is summarized in Table 1. Patients that begin with arthritis showed significant association with higher elevated C reactive protein and longer PsA disease duration. Longer time till arthritis appearance as well as more prevalence of Dactylitis was more observed in patients that begin with Pso before arthritis. <h3>Conclusion</h3> Significantly higher prevalence of CRP elevation in patients that begin with arthritis. Higher prevalence of dactylitis and longer time until articular manifestation was observed in patients that begin with Pso. <h3>Reference</h3> [1]J Am Acad Dermatol. 2019 Dec;81(6):1283-1291. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1436 BIOLOGIC THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS TUNISIAN PATIENTS
Authors: M. Ardhaoui, D. Khalifa, O. Farhat, R. Fakhfakh, N. El Amri, K. Baccouche, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children under the age of 16. Biologic therapy significantly improved the management and prognosis of this disease. <h3>Objectives</h3> We aimed to evaluate the indications, clinical efficacy and safety of biotherapy for the treatment of JIA in a tunisian population. <h3>Methods</h3> This is a monocentric retrospective and observational study including patients followed for JIA (ILAR criteria) in the Rheumatology department of Sousse in Tunisia. <h3>Results</h3> Fifty-five children (28 girls and 27 boys) were included. The mean age was 13.6 years. The predominant subtypes of JIA were the seronegative polyarticular JIA (38.2%), and the seronegative oligoarticular form and juvenile spondyloarthritis (16.4% each). Besides biologics, our patients received non steroidal anti-inflammatory drugs (61.8%), oral corticosteroids (67.3%), and pulse steroid therapy in 47.3% of cases. Methotrexate was used for 65.5% of patients. Twenty-four patients were treated with biologics, with a prevalence of 41.8%. The mean age at the beginning of biotherapy was 12 years, with a mean time for initiation of 5 years. The main indications were the first and second-line treatments failure (29.1%) and their side effects (12.7%). The most frequently used biologics were TNF alpha blockers: Etanercept (9 patients), Infliximab (6 patients), Certolizumab and Adalimumab (2 patients each). Anti-Interleukin-6 (Tocilizumab) was used in the systemic JIA form for 4 patients. The mean duration of treatment with biologics was 3.55 years. A trend towards lower disease activity was observed with steroid therapy stopped in 25%. Five patients switched biologics. The overall safety profile was good. No serious adverse drug events occurred except anaphylaxis in 2 cases: 1 with Tocilizumab and one with Infliximab. The other side effects were hepatic toxicity with elevated transaminases (2 patients) and moderate cutaneous infection (1 patient). <h3>Conclusion</h3> Biologics have provided interesting new therapeutic alternatives in Tunisian patients with JIA, despite the delay of their initiation. However, the long-term side effects of modulating the immune system are not yet fully understood in this young population. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1205 IMPACT OF CATASTROPHIZING ON PAIN, FUNCTION, AND PHYSICAL PERFORMANCE IN PATIENTS WITH KNEE OSTEOARTHRITIS
Authors: N. Takhrifa, F. Z. Taik, A. Adnine, N. Soba, M. Fourtassi, F. E. Abourazzak
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Osteoarthritis (OA) is the most common osteoarticular disease, with pain and functional discomfort being the main symptoms leading patients to consult. Catastrophism is defined as an exaggerated negative reaction to an anxiety-provoking stimulus. It is considered to be an important cognitive factor in painful conditions, particularly in osteoarthritis. <h3>Objectives</h3> The aim of this study was to assess the level of catastrophizing and to determine the relationship between catastrophizing and pain intensity, functional impact, and physical performance. <h3>Methods</h3> This is a cross-sectional study conducted in the rheumatology department. Sociodemographic information and comorbidities were collected. Pain was assessed by Visual Analogic Scale (VAS); functional impact by the Lequesne knee index and radiographic stage by the Kellgren and Lawrence scale. The level of catastrophizing was assessed by the validated Moroccan version of the Pain Catastrophizing Scale (PCS). A PCS ⩾ 30 indicate high level of catastrophizing. Physical performance was assessed by the 06min walk test and IPAQ questionnaire. <h3>Results</h3> A total of 178 patients were included. The sociodemographic and clinical characteristics of the patients are presented in (Table 1). Univariate and multivariate analysis showed the Lequesne index (p=0.008) and anxiety (0.001) were statistically significantly associated with the level of catastrophizing. <h3>Conclusion</h3> The level of catastrophizing seems to have an impact on function and anxiety. However, there was no association between catastrophizing and the walking test. Catastrophism is an important factor to assess at the beginning of the management of a patient with OA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1567 DIAGNOSIS OF SACROILIITIS USING LOW DOSE CT COMPARED TO MRI
Authors: P. W. V. Chan, S. L. Lau, J. F. Griffith, J. So, H. So, L. S. Tam
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Establishing a correct diagnosis of sacroiliitis is key to the early diagnosis of axial SPA. Low-dose computed tomography (LDCT) is helpful at revealing the structural changes (erosion, sclerosis and ankylosis) of sacroiliitis. How does LDCT compare with MRI for identifying sacroiliitis? <h3>Objectives</h3> This study compares LDCT and MRI in the diagnosis of sacroiliitis in patients with suspected axial spondyloarthritis (axSpA). <h3>Methods</h3> 25 patients [36 ± 7 years; female 16 (64%)] with back pain over three months and age under 45, clinically suspected of axSpA underwent radiography, LDCT and MRI of the SIJ. All imaging studies were assessed by an experienced radiologist. Radiographs and LDCT revealed erosions, bone sclerosis and ankylosis. MRI, in addition to these structural changes, also revealed osteitis and enthesitis. <h3>Results</h3> Out of the 25 patients, 8 (32%) had radiographic-sacroiliitis. Twelve (48%) patients had sacroiliitis on both LDCT and MRI, including 6 patients with radiographic-sacroiliitis and 6 patients with non-radiographic-sacroiliitis. There is no evidence of sacroiliitis on both LDCT and MRI for one patient, who was reported to have sacroiliitis on x-ray. No diagnosis could be made to 10 (40%) patients due to lack of evidence from imaging and 3 (12%) patients were diagnosed as osteitis condensans ilii. Agreement between MRI and LDCT was 100%, Cohen's kappa coefficient was k=1, positive predictive value was 1, and negative predictive value was 1. Using MRI as the gold standard, sensitivity and specificity of LDCT were 1 and 1 respectively. While the sensitivity and specificity of x-ray were 0.5 and 0.85 respectively. <h3>Conclusion</h3> Low dose CT and MRI showed comparable sensitivity in detecting sacroiliitis. If access to MRI is limited, LDCT is a good alternative to detect sacroiliitis in patients with suspected axSpA. <h3>Reference</h3> [1]Caetano AP, Mascarenhas VV, Machado PM. Axial Spondyloarthritis: Mimics and Pitfalls of Imaging Assessment. Front Med (Lausanne). 2021;8:658538. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Pui Wing, Vivien CHAN: None declared, Sze-Lok Lau: None declared, James F Griffith: None declared, Jacqueline So: None declared, Ho So Speakers bureau: Abbvie, Boehringer Ingelheim, Fosun Industrial, GSK, Janssen, Pfizer, Consultant of: Abbvie, GSK, Grant/research support from: Fosun Industrial, Lai-Shan Tam Consultant of: AbbVie, AstraZenaca, Boehringer Ingelheim, Eli Lilly, Janssen, Pfizer, and Sanofi, Grant/research support from: Amgen, Boehringer Ingelheim, GSK, Janssen, Novartis and Pfizer.
AB1463 AVASCULAR NECROSIS BONE IN CHRONIC GRAFT-VERSUS-HOST DISEASE POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Authors: M. Ibáñez Martínez, S. Pastor Navarro, B. Miguel Ibáñez, C. C. Chacón Vélez, A. I. Turrión Nieves, O. Martínez González, S. Gómez Castro, C. Montila Morales, C. Hidalgo Calleja
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Graft-versus-host disease (GVHD) is the most frequent complication after allogeneic hematopoietic cell transplantation (allo-HCT). The first line of treatment for moderate-severe chronic GVHD (cGVHD) is usually high and prolonged doses of corticosteroid therapy. Avascular necrosis bone (AVN) is a complication that appears after allo-HCT with an incidence of 5% to 19%. The exact mechanism by which it occurs is unkown and probably multifactorial. However, it has been associated with the presence and treatment of cGVHD. <h3>Objectives</h3> To describe the prevalence of AVN and its clinical characteristics in a cohort of patients with cGVHD evaluated in a multidisciplinary practice. <h3>Methods</h3> Descriptive and prospective observational study to describe the prevalence and characterization of AVN in a cohort of 132 patients with steroid-refractory cGVHD in multidisciplinary consultation. Variables related to baseline disease, transplantation and clinical manifestations of cGVHC are collected. <h3>Results</h3> 14 (10,6%) developed AVN confirmed by magnetic resonance imaging. The transplant-related characteristics and clinical features of cGVHD are detailed in Table 1. All of them had been receiving steroids. The average time from transplantation to AVN was 2,5 years (0-5,5). The mean age of AVN diagnosis was 46 years (range 17-65). Three patients had developed the AVN before the first visit.The diagnosis of AVN was during follow-up in the rest of them, with a mean onset of 23 months (1-48). 64,3% had more than one joint affected. The head of femur was the most commonly affected area (64,3%), followed by knee (35,7%). Other sites also affected were elbow, humeral head and ankle, with one case each. 64,3% needed joint replacement. <h3>Conclusion</h3> AVN in our cohort is a relatively common complication and it occurs in moderate-severe cGVHD. These patients present pain and limitation in range of motion and these manifestations may also appear in the context of GVHD itself. Early recognition is a challenge to avoid misdiagnosis and the risk of overtreatment with steroids that would increase the progression of the lesion. <h3>References</h3> [1]Law AD et al. Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2021 May;100(5):1311-1319. [2]Bar M et al. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020 Oct;26(10):1784-1802. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1345 COVID-19 AND ADVERSE MENTAL HEALTH OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: M. Ghali, M. Ardhaoui, J. Mahbouba, S. Zrour, I. Bejia, M. Touzi, N. Bergaoui
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The COVID-19 outbreak is known to increase the fear level of most patients with chronic diseases. Patients with rheumatoid arthritis (RA) are very vulnerable to environmental stress. During this pandemic, the psychological pressure may be further increased due to the perplexing nature of information about the risk of infection in RA patients. <h3>Objectives</h3> The objective of this study was to determine the impact of the COVID-19 pandemic on the mental health of RA patients and to investigate associated factors. <h3>Methods</h3> This is a cross-sectional study of 190 patients with RA who met the ACR/EULAR 2010 criteria. For each patient, we collected sociodemographic, clinical, and biological data. Depression and anxiety were assessed by the Hospital Anxiety and Depression scale (HADs) and disease activity by the DAS-28 score. <h3>Results</h3> The average age of our patients was 55 years with a female predominance (86.3%). The average duration of the disease was 8 years. The mean DAS 28 score was 4.1 ±1.03. The disease was deforming in 52.9% of cases. All of us patients were on disease-modifying therapy, 87.1% were on methotrexate and 12.9% were on biotherapy. Sixty patients (31.57%) had contracted SARS-CoV-2.During the pandemic, depression was present in 38.4% of patients. It was mild in 33.1% of cases, moderate in 4.1%, and severe in 1.2% with a mean HADs depression score of 4.4 ± 3.1. This score was significantly higher in patients with a history of SARS-COV-2 infection in a family member (p=0,002), comorbidities (p&lt;0.001), joint deformities (p=0.008), and high disease activity (p&lt;0.001). Anxiety was present in 55.6% of patients. It was mild in 32.6% of cases, moderate in 20.6%, and severe in 2.4% of cases with a mean HADs anxiety of 6.4 ± 3.9. The presence of anxiety was correlated with fear of COVID-19, higher disease activity, the presence of comorbidities, and the presence of deformities (p&lt;0.001 for all cases). This score was also significantly higher in the illiterate (p&lt;0.001) and unemployed patients (p=0.001). <h3>Conclusion</h3> In our study, depression and anxiety were frequent in RA patients during the COVID-19 pandemic. These psychological disorders were more common in patients with active and disabling RA associated with comorbidities. As the pandemic continues, more patients are susceptible to experience anxiety and depression. Therefore, rheumatologists must remain vigilant to these psychological alterations and provide the necessary support. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1244 CHANGES IN THE GUT MICROBIOTA OF GOUT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: X. Y. Yin, G. X. Wang, X. Song, D. Qiao, Q. Y. Su, Q. Yu, P. F. He, X. Li, S. X. Zhang
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Gout is a crystal-related joint disease caused by the deposition of monosodium urate crystals in or around the joints[1][2]. Structural changes or imbalances in the gut microbiota could cause metabolic disorders and participate in the synthesis of purine-metabolizing enzymes and the release of inflammatory cytokines, which is closely related to the occurrence and development of metabolic, immune disease and gout. <h3>Objectives</h3> This study aimed to explore the disorders of intestinal microflora alpha diversity and microbial community composition in patients with gout through meta-analysis. <h3>Methods</h3> According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we comprehensively searched the databases of PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP, CBM, and Wanfang database without language restrictions. We obtained data related to the alpha diversity index(Shannon index, Simpson index, ACE, Chao1, Observed species) and analyzed phylum and genus composition. <h3>Results</h3> Nine studies, including 423 gout patients and 458 healthy controls(HCs), were included in our analysis. The Simpson index of gout was significantly lower than that of HCs (SMD=-1.037, 95%CI:-1.959~-0.115). There was no significant difference in other alpha diversity indexes between the two groups(Shannon index: SMD=-0.429, 95%CI:-0.900~0.041; ACE: SMD=0.102, 95%CI:-0.918~1.122; Chao1: SMD=0.863, 95%CI:-0.267~1.993; Observed species: SMD= -1.962, 95%CI:-5.011~1.088). We collected the relative abundance of 30 genera of gout and classified them according to the species affiliation. The results showed that the relative abundance of microflora in <i>proteobacteria</i> was significantly lower than that of HCs(SMD= -0.498, 95%CI:-0.911~-0.086). However, the relative abundance of microflora in <i>Fusobacteria</i>(SMD=0.589, 95%CI:0.249~0.929), <i>Actinobacteria</i>(SMD=0.546, 95%CI:0.207~0.885), and <i>Bacteroides</i>(SMD=0.395, 95%CI:0.035~0.755) increased in gout patients. We did not observe significant changes in the gut microbes of <i>Firmicutes</i>(SMD=-0.210, 95%CI:-0.456~0.036). <h3>Conclusion</h3> This systematic evaluation and meta-analysis showed that the impact of gout microbiota was mainly observed at the level of phylum and genus, but limited to microbial diversity. It is necessary to further study the role and function of specific bacteria and their influence on the physiology and pathology of gout. <h3>References</h3> [1]Wang, Z. et al. Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout. Front Cell Infect Microbiol 12, 935723, doi:10.3389/fcimb.2022.935723 (2022). [2]Chu, Y. et al. Metagenomic analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes 7, 66, doi:10.1038/s41522-021-00235-2 (2021). <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.